tradingkey.logo

Telomir Pharmaceuticals Inc

TELO
1.410USD
+0.040+2.92%
收盤 12/19, 16:00美東報價延遲15分鐘
47.70M總市值
虧損本益比TTM

Telomir Pharmaceuticals Inc

1.410
+0.040+2.92%

關於 Telomir Pharmaceuticals Inc 公司

Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.

Telomir Pharmaceuticals Inc簡介

公司代碼TELO
公司名稱Telomir Pharmaceuticals Inc
上市日期Feb 09, 2024
CEOAminov (Erez)
員工數量- -
證券類型Ordinary Share
年結日Feb 09
公司地址900 West Platt Street, Suite 200
城市TAMPA
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編33606
電話18138642562
網址https://telomirpharma.com/
公司代碼TELO
上市日期Feb 09, 2024
CEOAminov (Erez)

Telomir Pharmaceuticals Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.01M
+3288.20%
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Independent Director
Independent Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Erez Aminov
Mr. Erez Aminov
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.01M
+3288.20%
Mr. Matthew Pratt Whalen, CPA
Mr. Matthew Pratt Whalen, CPA
Independent Director
Independent Director
--
--
Mr. Alan Weichselbaum
Mr. Alan Weichselbaum
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Matthew Paul Del Giudice, M.D.
Dr. Matthew Paul Del Giudice, M.D.
Independent Director
Independent Director
--
--
Mr. Edward MacPherson
Mr. Edward MacPherson
Independent Director
Independent Director
--
--

收入明細

由於公司未披露,未能獲取相關數據
由於公司未披露,未能獲取相關數據
業務
地區
由於公司未披露,未能獲取相關數據

股東統計

更新時間: 12月4日 週四
更新時間: 12月4日 週四
持股股東
股東類型
持股股東
持股股東
佔比
Bay Shore Trust
19.58%
Mira Pharmaceuticals, Inc
10.24%
McNulty (Brian Patrick)
5.46%
DeJoria (John Paul)
5.16%
The Vanguard Group, Inc.
3.20%
其他
56.35%
持股股東
持股股東
佔比
Bay Shore Trust
19.58%
Mira Pharmaceuticals, Inc
10.24%
McNulty (Brian Patrick)
5.46%
DeJoria (John Paul)
5.16%
The Vanguard Group, Inc.
3.20%
其他
56.35%
股東類型
持股股東
佔比
Corporation
29.82%
Individual Investor
15.16%
Investment Advisor
4.96%
Investment Advisor/Hedge Fund
1.05%
Hedge Fund
0.68%
Research Firm
0.13%
其他
48.20%

機構持股

更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
97
2.75M
8.52%
-985.35K
2025Q2
89
13.66M
45.90%
+660.23K
2025Q1
87
13.90M
46.70%
+955.11K
2024Q4
74
13.75M
46.22%
+2.38M
2024Q3
65
14.68M
49.58%
+3.19M
2024Q2
47
12.97M
43.79%
+1.79M
2024Q1
17
12.67M
42.78%
+1.58M

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Bay Shore Trust
6.73M
20.85%
-89.00K
-1.30%
Dec 31, 2024
McNulty (Brian Patrick)
1.88M
5.82%
-49.00K
-2.54%
Dec 31, 2024
DeJoria (John Paul)
1.77M
5.5%
+1.77M
--
Sep 09, 2025
The Vanguard Group, Inc.
1.12M
3.46%
-139.96K
-11.12%
Jun 30, 2025
Aminov (Erez)
1.01M
3.13%
+979.88K
+3288.20%
Dec 31, 2024
Eagle (Craig)
487.81K
1.51%
--
--
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
357.01K
1.11%
-761.63K
-68.09%
Jun 30, 2025
Millennium Management LLC
247.70K
0.77%
+247.70K
--
Jun 30, 2025
Geode Capital Management, L.L.C.
196.88K
0.61%
-232.37K
-54.13%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
iShares Micro-Cap ETF
0.01%
iShares Russell 2000 ETF
0%
Global X Russell 2000 ETF
0%
ProShares UltraPro Russell2000
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
iShares Russell 2000 Value ETF
0%
iShares Russell 2000 Growth ETF
0%
iShares Micro-Cap ETF
佔比0.01%
iShares Russell 2000 ETF
佔比0%
Global X Russell 2000 ETF
佔比0%
ProShares UltraPro Russell2000
佔比0%
ProShares Hedge Replication ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
iShares Russell 2000 Value ETF
佔比0%
iShares Russell 2000 Growth ETF
佔比0%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Telomir Pharmaceuticals Inc的前五大股東是誰?

Telomir Pharmaceuticals Inc的前五大股東如下:
Bay Shore Trust
持有股份:6.73M
佔總股份比例:20.85%。
McNulty (Brian Patrick)
持有股份:1.88M
佔總股份比例:5.82%。
DeJoria (John Paul)
持有股份:1.77M
佔總股份比例:5.50%。
The Vanguard Group, Inc.
持有股份:1.12M
佔總股份比例:3.46%。
Aminov (Erez)
持有股份:1.01M
佔總股份比例:3.13%。

Telomir Pharmaceuticals Inc的前三大股東類型是什麼?

Telomir Pharmaceuticals Inc 的前三大股東類型分別是:
Bay Shore Trust
Mira Pharmaceuticals, Inc
McNulty (Brian Patrick)

有多少機構持有Telomir Pharmaceuticals Inc(TELO)的股份?

截至2025Q3,共有97家機構持有Telomir Pharmaceuticals Inc的股份,合計持有的股份價值約為2.75M,占公司總股份的8.52% 。與2025Q2相比,機構持股有所增加,增幅為-37.38%。

哪個業務部門對Telomir Pharmaceuticals Inc的收入貢獻最大?

在--,--業務部門對Telomir Pharmaceuticals Inc的收入貢獻最大,創收--,占總收入的--% 。
KeyAI